By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has ...

GSK Plc is planning five simultaneous late-stage trials for a cancer drug it hopes will be a blockbuster, as new Chief ...

GSK has released the first clinical data for an experimental injectable cancer drug that showed early signs of activity ...

Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug ...

Mo-Rez achieved confirmed objective response rates of 62% in patients with platinum-resistant ovarian cancer. Credit: MMD ...

GSK (NYSE:GSK) is beginning to show a more assertive shift in strategy as CEO Luke Miels pushes the company toward higher-risk oncology development, with plans to launch five simultaneous late-stage ...

The phase 1 BEHOLD-1 trial of B7-H4-directed mocertatug rezetecan (Mo-Rez, formerly HS-20093) showed an objective response rate (ORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in ...

GSK's Mocertatug Rezetecan (Mo-Rez) has shown positive early results in treating ovarian and endometrial cancers, shrinking ...

A cancer drug licensed by GSK from China has delivered promising results in a trial, in a boost for the company’s oncology strategy. The FTSE 100 group said Mo-Rez had an “objective response rate” — ...

SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has ...

GSK launches Mapping Myelofibrosis to help chart course for those affected by the disease. Myelofibrosis is a complex blood cancer that impacts nearly 25,000 people in the U.S. MF impacts nearly ...